- |||||||||| elafibranor (GFT505) / Genfit, Ocaliva (obeticholic acid) / Intercept, NGM282 / NGM Biopharmaceuticals
Journal: Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. (Pubmed Central) - Jul 13, 2019 Patients with NAFLD have a significant increase in cardiovascular disease risk. For biopsy-proven NASH, vitamin E and pioglitazone are the recommended medical treatments in addition to lifestyle modification.
- |||||||||| aldafermin (NGM282) / NGM Biopharma
Enrollment change, Trial completion date, Trial primary completion date: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jun 6, 2018 P2, N=250, Recruiting, Further study of NGM282 is warranted in this patient population. N=140 --> 250 | Trial completion date: Apr 2018 --> Sep 2019 | Trial primary completion date: Apr 2018 --> Sep 2019
- |||||||||| aldafermin (NGM282) / NGM Biopharma
Enrollment open, Enrollment change, Trial primary completion date: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Mar 13, 2017 P2, N=140, Recruiting, Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Dec 2016 --> Apr 2018
- |||||||||| aldafermin (NGM282) / NGM Biopharma
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Aug 24, 2016 P2b, N=36, Completed, Recruiting --> Completed | N=60 --> 31 | Trial primary completion date: Sep 2017 --> Jan 2017 Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016
- |||||||||| aldafermin (NGM282) / NGM Biopharma
Enrollment closed: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Aug 24, 2016 P2, N=80, Active, not recruiting, Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016 Recruiting --> Active, not recruiting
|